Kronenfeld Mark A. 4
4 · Pacira BioSciences, Inc. · Filed Jun 12, 2023
Insider Transaction Report
Form 4
Kronenfeld Mark A.
Director
Transactions
- Sale
Common Stock
2023-06-08$37.04/sh−15,000$555,600→ 17,897 total - Exercise/Conversion
Common Stock
2023-06-08$29.90/sh+15,000$448,500→ 32,897 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-06-08−15,000→ 0 totalExercise: $29.90Exp: 2023-06-11→ Common Stock (15,000 underlying)
Footnotes (3)
- [F1]The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.72 to $37.43, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The option shares vested in 24 equal successive monthly installments over the 24-month period following the date of grant, subject to the reporting person's continued service as a director.